Table 4.

Phase III bococizumab trials (ongoing)

Study	Population	Comparison	Estimated completion
SPIRE-HF [99] https://clinicaltrials.gov/ct2/show/NCT01968980	Pts with HeFH with high and very high CVD risk (with statin therapy)	Bococizumab vs. PL at 12 weeks	January 2016
SPIRE-HR [100] https://clinicaltrials.gov/ct2/show/NCT01968954	Pts with high and very high CVD risk (with statin therapy)	Bococizumab vs. PL at 12 weeks	January 2016
SPIRE-LDL [101] https://clinicaltrials.gov/ct2/show/NCT01968967	Pts with high and very high CVD risk (with statin therapy)	Bococizumab vs. PL at 12 weeks	December 2015
SPIRE-1 [102] https://clinicaltrials.gov/ct2/show/NCT01975376	Pts with high and very high CVD risk (with lipid-lowering therapy)	Bococizumab vs. PL at 5 years (effects on major CV events)	August 2017
SPIRE-2 [103] https://clinicaltrials.gov/ct2/show/NCT01975389	Pts with high and very high CVD risk (with lipid-lowering therapy)	Bococizumab vs. PL at 5 years (effects on major CV events)	August 2017

CV cardiovascular, CVD cardiovascular disease, HeFH heterozygous familial hypercholesterolemia, PL placebo